Aaron Tachibana, who holds the roles of Chief Financial Officer and Chief Operating Officer at Personalis, Inc. (NASDAQ:PSNL), completed a notable insider transaction on January 22, 2026. On that day, Tachibana sold 1,201 shares of Personalis common stock at $11.50 per share, generating proceeds totaling $13,811. This price point was near the stock’s 52-week peak of $11.50, reflecting robust performance with shares rising approximately 65% over the previous year, according to InvestingPro data.
In a related transaction on the same date, Tachibana exercised stock options to acquire 1,201 shares at an exercise price of $9.16 per share, amounting to a total of $11,001. This dual activity of exercising options followed by selling shares indicates a strategic move in managing his holdings ahead of the company’s upcoming earnings report, scheduled for February 19, 2026.
Following these transactions, Tachibana’s direct ownership in Personalis stands at 164,458 shares. Investment analysis from InvestingPro highlights the company’s solid financial foundation, noting a balance sheet that boasts more cash than debt. Yet, valuation metrics suggest the company’s shares may currently be trading above their intrinsic Fair Value, warranting consideration for investors assessing entry points.
Alongside the insider trades, Personalis recently secured favorable Medicare coverage for its NeXT Personal test, designed for monitoring recurrence in stage II and III breast cancer patients. The Centers for Medicare & Medicaid Services (CMS) set reimbursement rates at $3,878 for the NeXT Personal Dx Breast MRD Recurrence Monitoring Test and $1,158 for the NeXT Personal Single Plasma Test. Importantly, these rates are effective retroactively from October 7, 2025. Notably, CMS announced adjustments effective December 1, 2025, increasing reimbursements to $4,266 for the Dx Breast MRD Recurrence Monitoring Test and $1,164 for the Single Plasma Test.
In other corporate developments, Personalis has filed a prospectus supplement indicating intent to potentially raise $100 million through a stock offering, appointing Piper Sandler & Co. and BTIG, LLC as sales agents. Simultaneously, a recent publication in Clinical Cancer Research demonstrated that the NeXT Personal blood test shows promise in predicting cancer treatment response for patients undergoing immunotherapy.
Market analysts acknowledge these advancements, with BTIG affirming a Buy rating on Personalis and elevating its price target from $11.00 to $12.00. They view the Medicare coverage decision as a significant risk mitigator for the company’s growth prospects.